QR-kod

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (<i>NTRK)</i> gene fusions. These <i>NTRK</i> gene fusions are oncogenic drivers found in most tumour types...

Full beskrivning

Sparad:
Huvudupphov: D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska, Barbara Melosky, Jonathan Noujaim, Bibiana Purgina, Dean Ruether, Christine E. Simmons, Denis Soulieres, Emina Emilia Torlakovic, Ming-Sound Tsao
Materialtyp: Artigo
Språk:Inglês
Utgiven: MDPI AG 2021-01-01
Serie:Current Oncology
Ämnen:
NTRK
larotrectinib
entrectinib
targeted therapy
molecular testing
oncogenic drivers
Länkar:https://www.mdpi.com/1718-7729/28/1/53
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk